About: Plant‐produced candidate countermeasures against emerging and reemerging infections and bioterror agents

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Plant‐produced candidate countermeasures against emerging and reemerging infections and bioterror agents Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Plant‐produced candidate countermeasures against emerging and reemerging infections and bioterror agents
Creator	Yusibov, Vidadi Kushnir, Natasha Streatfield, Stephen
Source	Medline; PMC
abstract	Despite progress in the prevention and treatment of infectious diseases, they continue to present a major threat to public health. The frequency of emerging and reemerging infections and the risk of bioterrorism warrant significant efforts towards the development of prophylactic and therapeutic countermeasures. Vaccines are the mainstay of infectious disease prophylaxis. Traditional vaccines, however, are failing to satisfy the global demand because of limited scalability of production systems, long production timelines and product safety concerns. Subunit vaccines are a highly promising alternative to traditional vaccines. Subunit vaccines, as well as monoclonal antibodies and other therapeutic proteins, can be produced in heterologous expression systems based on bacteria, yeast, insect cells or mammalian cells, in shorter times and at higher quantities, and are efficacious and safe. However, current recombinant systems have certain limitations associated with production capacity and cost. Plants are emerging as a promising platform for recombinant protein production due to time and cost efficiency, scalability, lack of harboured mammalian pathogens and possession of the machinery for eukaryotic post‐translational protein modification. So far, a variety of subunit vaccines, monoclonal antibodies and therapeutic proteins (antivirals) have been produced in plants as candidate countermeasures against emerging, reemerging and bioterrorism‐related infections. Many of these have been extensively evaluated in animal models and some have shown safety and immunogenicity in clinical trials. Here, we overview ongoing efforts to producing such plant‐based countermeasures.
has issue date	2015-09-21(xsd:dateTime)
bibo:doi	10.1111/pbi.12475
bibo:pmid	26387510
has license	no-cc
sha1sum (hex)	6a9ef100908ba7ae243e76a17806b56590cf30a8
schema:url	https://doi.org/10.1111/pbi.12475
resource representing a document's title	Plant‐produced candidate countermeasures against emerging and reemerging infections and bioterror agents
has PubMed Central identifier	PMC7167919
has PubMed identifier	26387510
schema:publication	Plant Biotechnol J
resource representing a document's body	covid:6a9ef100908ba7ae243e76a17806b56590cf30a8#body_text
is schema:about of	named entity 'KEYWORDS' named entity 'bioterrorism' named entity 'recombinant protein' named entity 'fusion protein' named entity 'ricin' named entity 'protein' named entity 'subunit vaccine' named entity 'antigenic shift' named entity 'yellow fever' named entity 'plague' named entity 'botulism' named entity 'virus' named entity 'viral entry' named entity 'tetravalent' named entity 'delirium' named entity 'amino acids' named entity 'scFv' named entity 'epitopes' named entity 'serum' named entity 'HAC1' named entity 'immunization' named entity 'pathogens' named entity 'flavivirus' named entity 'ricin' named entity 'antigen' named entity 'Germany' named entity 'nucleoprotein' named entity 'severe allergic reactions' named entity 'influenza' named entity 'protein' named entity 'immunogenicity' named entity 'A(H1N1)pdm09' named entity 'N-terminal fragment' named entity 'Botulinum neurotoxin' named entity 'botulism' named entity 'hybridoma' named entity 'encephalitis' named entity 'VHFs' named entity 'type 2' named entity 'carrot' named entity 'glucocerebrosidase' named entity 'IgG' named entity 'Asia' named entity 'Canada' named entity 'arabinogalactan' named entity 'plague' named entity 'IgG' named entity 'mucosal' named entity 'bioterror' named entity 'WNV' named entity 'protein' named entity 'antigen' named entity 'Alhydrogel' named entity 'tobacco' named entity 'ZMapp' named entity 'IgG' named entity 'bioterrorism' named entity 'vaccine' named entity 'water soluble' named entity 'N. benthamiana' named entity 'IgA antibody' named entity 'viruses' named entity 'vaccine' named entity 'protective antibodies' named entity 'anaphylaxis' named entity 'naturally occurring' named entity 'pathogens' named entity 'zoonotic infection' named entity 'Rift Valley fever' named entity 'N-linked glycans' named entity 'virus' named entity 'monoclonal antibody' named entity 'B. anthracis' named entity 'Fc gamma receptor' named entity 'West Nile' named entity 'immunogenicity' named entity 'vaccine' named entity 'Anthrax' named entity 'SARS-CoV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software